Status:
UNKNOWN
Urinary Transglutaminase 2 as a Biomarker for Kidney Allograft Fibrosis
Lead Sponsor:
Asan Medical Center
Conditions:
Kidney Allograft Fibrosis
Kidney Transplant Failure and Rejection
Eligibility:
All Genders
18-70 years
Brief Summary
The aim of this study is to verify the ability of transglutaminase type 2 to predict rejection or chronic allograft nephropathy of renal allograft. On the basis of biomolecular mechanisms aggravating ...
Eligibility Criteria
Inclusion
- kidney transplant recipients from cadaveric or living donors
- kidney transplant recipients who take immunosuppressants regularly
- kidney transplant recipients who voluntarily agree to participate in this trial
Exclusion
- multiorgan transplant recipients
- kidney transplant recipients with active infection
- kidney transplant recipients with alcohol or drug addiction
Key Trial Info
Start Date :
August 29 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT03487861
Start Date
August 29 2017
End Date
December 31 2020
Last Update
April 4 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, South Korea, 05505